Type: cell_therapy
Status: Active — First Patients Dosed
Developer: Vertex Pharmaceuticals
VX-264 encapsulates the same iPSC-derived islet cells used in VX-880 within a proprietary immunoprotective device, eliminating chronic immunosuppression. The device is implanted subcutaneously and allows oxygen and nutrient exchange while blocking immune cells. First patients dosed in 2024; preliminary 6-month data (2025) shows detectable C-peptide production. Full Phase I/II readout expected 2026.
Stem cell-derived islet cells loaded into a macroencapsulation device with semipermeable membranes (pore size allows insulin, glucose, and nutrients to pass but excludes T cells and antibodies). Implanted subcutaneously in the forearm for easy monitoring and retrieval.
Year: 2025-2026